Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
The company is headquartered in West Conshohocken, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -4.92 Increased by +7.87% | -6.91 Increased by +28.80% |
| Aug 7, 24 | -7.10 Decreased by -51.39% | -7.53 Increased by +5.71% |
| May 7, 24 | -7.38 Decreased by -74.47% | -6.28 Decreased by -17.52% |
| Feb 28, 24 | -5.68 Decreased by -14.06% | -5.28 Decreased by -7.58% |
| Nov 6, 23 | -5.34 Decreased by -12.42% | -4.93 Decreased by -8.32% |
| Aug 8, 23 | -4.69 Decreased by -13.29% | -4.58 Decreased by -2.40% |
| May 9, 23 | -4.23 Decreased by -25.89% | -4.94 Increased by +14.37% |
| Feb 23, 23 | -4.98 Decreased by -31.75% | -4.56 Decreased by -9.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 62.17 M Increased by +N/A% | -106.96 M Decreased by -8.33% | Decreased by -172.04% Decreased by N/A% |
| Jun 30, 24 | 14.64 M Increased by +N/A% | -151.97 M Decreased by -77.12% | Decreased by -1.04 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -147.54 M Decreased by -89.66% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 770.00 K Increased by +N/A% | -112.19 M Decreased by -28.09% | Decreased by -14.57 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -98.74 M Decreased by -19.40% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -85.80 M Decreased by -19.98% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -77.79 M Decreased by -35.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -87.59 M Decreased by -35.69% | Decreased by N/A% Decreased by N/A% |